Abstract

Angiogenesis has key roles in development and in the progression of human diseases such as cancer. Consequently, identifying the novel markers and regulators of angiogenesis is a critical task. The dioxin receptor (AhR) contributes to vascular homeostasis and to the endothelial response to toxins, although the mechanisms involved are largely uncharacterized. Here, we show that AhR-null mice (AhR(-/-)) have impaired angiogenesis in vivo that compromises tumor xenograft growth. Aortic rings emigration experiments and RNA interference indicated that AhR(-/-) endothelial cells failed to branch and to form tube-like structures. Such a phenotype was found to be vascular endothelial growth factor (VEGF)-dependent, as AhR(-/-) aortic endothelial cells (MAECs) secreted lower amounts of active VEGF-A and their treatment with VEGF-A rescued angiogenesis in culture and in vivo. Further, the addition of anti-VEGF antibody to AhR(+/+) MAECs reduced angiogenesis. Treatment under hypoxic conditions with 2-methoxyestradiol suggested that HIF-1alpha modulates endothelial VEGF expression in an AhR-dependent manner. Importantly, AhR-null stromal myofibroblasts produced increased transforming growth factor-beta (TGFbeta) activity, which inhibited angiogenesis in human endothelial cells (HMECs) and AhR(-/-) mice, whereas the co-culture of HMECs with AhR(-/-) myofibroblasts or with their conditioned medium inhibited branching, which was restored by an anti-TGFbeta antibody. Moreover, VEGF and TGFbeta activities cooperated in modulating angiogenesis, as the addition of TGFbeta to AhR(-/-) MAECs further reduced their low basal VEGF-A activity. Thus, AhR modulates angiogenesis through a mechanism requiring VEGF activation in the endothelium and TGFbeta inactivation in the stroma. These data highlight the role of AhR in cardiovascular homeostasis and suggest that this receptor can be a novel regulator of angiogenesis during tumor development.

Highlights

  • Angiogenesis, on the other hand, depends on the characteristics of the endothelial cells and on the interactions that they establish with other stromal cells, in particular with fibroblasts and pericytes [13]

  • Despite the fact that fibroblasts have different properties depending on their tissue of origin, the analysis of ␣-smooth muscle actin-expressing myofibroblasts isolated from a panel of breast carcinomas revealed common patterns of gene expression [14], which supports their conserved role in the synthesis and maintenance of extracellular matrix (ECM) components

  • 5-␮m steps using a Zeiss LSM 510 confocal microscope. of aryl hydrocarbon (dioxin) receptor (AhR)-null transformed fibroblasts to induce tumors in mice, Wound closure experiments were performed using human endothelial cells (HMECs)-1 in we suggested that lack of AhR expression could compromise the absence or presence of AhR small interfering RNA (siRNA) essentially as described tumor development by reducing cell migration and/or angiogenesis [33]

Read more

Summary

EXPERIMENTAL PROCEDURES

Reagents and Cell Lines—Matrigel and FITC-labeled antiCD102 were purchased from BD Biosciences and mouse recombinant VEGF-A164 from Calbiochem. RNA was purified and used to analyze VEGF mRNA levels as indicated below This concentration of CoCl2 has been shown to efficiently mimic hypoxia in cell culture [41]. The contribution of hypoxia inducible factor-1␣ (HIF-1␣) in maintaining VEGF levels was determined by adding 5 ␮M 2-Me E2 to CoCl2-treated MAECs or to AhR small interfering RNA (siRNA)-transfected HMEC-1 cells. This concentration of 2-Me E2 was shown to induce degradation of HIF-1␣ in cultured cells [42, 43]. Tumor Xenografts—Aliquots of 5 ϫ 105 B16F10 cells (in 100 ␮l of phosphate-buffered saline) were injected subcutaneously

Primer sequences
Image Processing and Statistical
Loss of AhR Expression Impairs
Endothelial Cells Lacking AhR
DISCUSSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.